Ovid Net Receivables from 2010 to 2026
| OVID Stock | USD 1.58 0.02 1.25% |
Net Receivables | First Reported 2010-12-31 | Previous Quarter 300.4 K | Current Value 403.4 K | Quarterly Volatility 288.5 K |
Check Ovid Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ovid Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 365.4 K, Interest Expense of 3.3 M or Selling General Administrative of 22.9 M, as well as many indicators such as Price To Sales Ratio of 127, Dividend Yield of 0.0 or PTB Ratio of 1.06. Ovid financial statements analysis is a perfect complement when working with Ovid Therapeutics Valuation or Volatility modules.
Ovid | Net Receivables | Build AI portfolio with Ovid Stock |
Analyzing Ovid Therapeutics's Net Receivables over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Receivables has evolved provides context for assessing Ovid Therapeutics's current valuation and future prospects.
Latest Ovid Therapeutics' Net Receivables Growth Pattern
Below is the plot of the Net Receivables of Ovid Therapeutics over the last few years. It is Ovid Therapeutics' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ovid Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Receivables | 10 Years Trend |
|
Net Receivables |
| Timeline |
Ovid Net Receivables Regression Statistics
| Arithmetic Mean | 269,461 | |
| Geometric Mean | 149,914 | |
| Coefficient Of Variation | 107.08 | |
| Mean Deviation | 198,564 | |
| Median | 261,191 | |
| Standard Deviation | 288,529 | |
| Sample Variance | 83.2B | |
| Range | 1.1M | |
| R-Value | 0.38 | |
| Mean Square Error | 75.9B | |
| R-Squared | 0.15 | |
| Significance | 0.13 | |
| Slope | 21,803 | |
| Total Sum of Squares | 1.3T |
Ovid Net Receivables History
About Ovid Therapeutics Financial Statements
Ovid Therapeutics stakeholders use historical fundamental indicators, such as Ovid Therapeutics' Net Receivables, to determine how well the company is positioned to perform in the future. Although Ovid Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ovid Therapeutics' assets and liabilities are reflected in the revenues and expenses on Ovid Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ovid Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Receivables | 300.4 K | 403.4 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ovid Therapeutics is a strong investment it is important to analyze Ovid Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ovid Therapeutics' future performance. For an informed investment choice regarding Ovid Stock, refer to the following important reports:Check out the analysis of Ovid Therapeutics Correlation against competitors. For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Will Biotechnology sector continue expanding? Could Ovid diversify its offerings? Factors like these will boost the valuation of Ovid Therapeutics. Anticipated expansion of Ovid directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ovid Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.50) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets | Return On Equity |
Ovid Therapeutics's market price often diverges from its book value, the accounting figure shown on Ovid's balance sheet. Smart investors calculate Ovid Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Ovid Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Ovid Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Ovid Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.